Zimmer Biomet HoldingsXSWX:ZBH 65 ROA % is 4.13% as of Mar. 2026, which is 70% above its 10-year median of 2.43. GuruFocus rates XSWX:ZBH with a GF Score™ of 65/100 and a GF Value™ of CHF97.46 (Modestly Undervalued). The stock has 3 warning signs investors should review. Among 857 Medical Devices & Instruments companies, Zimmer Biomet Holdings ranks better than 63.24% on this metric.
ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Zimmer Biomet Holdings's annualizedNet Income for the quarter that ended in Mar. 2026 was CHF750 Mil.
Zimmer Biomet Holdings's average Total Assets over the quarter that ended in Mar. 2026 was CHF18,145 Mil. Therefore, Zimmer Biomet Holdings's annualized ROA % for the quarter that ended in Mar. 2026 was 4.13%.
The historical rank and industry rank for Zimmer Biomet Holdings's ROA % or its related term are showing as below:
XSWX:ZBH'
s ROA % Range Over the Past 10 Years
Min: -1.51 Med: 2.43 Max: 6.88
Current: 3.33
During the past 13 years, Zimmer Biomet Holdings's highest ROA % was 6.88%. The lowest was -1.51%. And the median was 2.43%.
XSWX:ZBH's ROA % is ranked better than 63.24% of 857
companies
in the Medical Devices & Instruments industry
Industry Median: 0.59
vs XSWX:ZBH: 3.33
ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A banks ROA % is typically well under 2%.
Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:
Note:
The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).
Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.
E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Devices subindustry, Zimmer Biomet Holdings's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zimmer Biomet Holdings ROA % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Zimmer Biomet Holdings's ROA % distribution charts can be found below:
* The bar in red indicates where Zimmer Biomet Holdings's ROA % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data,
the Net Income data used here is four times the quarterly (Mar. 2026) net income data.
ROA % is displayed in the 30-year financial page.
Zimmer Biomet Holdings (XSWX:ZBH) has a ROA % of 4.13% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Zimmer Biomet Holdings and its competitors. This is 70% above median its historical median of 2.43. According to the industry distribution chart, Zimmer Biomet Holdings ranks #315 out of 857 companies in the Medical Devices & Instruments industry, placing it in the top 36.8%.
Is Zimmer Biomet Holdings' ROA % too high?
Zimmer Biomet Holdings' current ROA % of 4.13% is 70% above median its 10-year median of 2.43. The Medical Devices & Instruments industry median ROA % is 0.59. Zimmer Biomet Holdings' value of 4.13% is 600% above this industry median. Based on the distribution chart, Zimmer Biomet Holdings ranks #315 out of 857 companies in the Medical Devices & Instruments industry, which is above the industry midpoint. Overall, Zimmer Biomet Holdings has a GF Score™ of 65/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Zimmer Biomet Holdings' ROA % compare to PEN and GMED?
According to the Medical Devices & Instruments industry distribution chart, Zimmer Biomet Holdings ranks #315 out of 857 companies for ROA %. This puts Zimmer Biomet Holdings in the upper half of its industry. The industry median ROA % is 0.59. Zimmer Biomet Holdings' value of 4.13% is 600% above this benchmark. While the company's 10-year median is 2.43 vs. the industry median of 0.59, Zimmer Biomet Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Medical Devices & Instruments company?
The median ROA % among Medical Devices & Instruments companies is 0.59, based on 857 companies in the industry. Companies in the top quartile (top 25%) have a ROA % significantly above this median, while those in the bottom quartile fall well below. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zimmer Biomet Holdings's current ROA % of 4.13% is 600% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Zimmer Biomet Holdings and its competitors. For the Medical Devices & Instruments industry, the median ROA % is 0.59 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zimmer Biomet Holdings's current ROA % is 4.13%, which is 70% above median its own 10-year median of 2.43. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zimmer Biomet Holdings stock overvalued right now?
Based on GuruFocus' analysis, Zimmer Biomet Holdings (XSWX:ZBH) is currently considered Modestly Undervalued. The stock's GF Value™ is CHF97.46, compared to a current price of CHF70.00 — trading 28.2% below its estimated fair value. The current ROA % is 4.13%, which is 70% above median its 10-year median of 2.43 and 600% above the Medical Devices & Instruments industry median of 0.59. Zimmer Biomet Holdings' overall GF Score™ is 65/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Zimmer Biomet Holdings (XSWX:ZBH), the current ROA % is 4.13% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Zimmer Biomet Holdings (XSWX:ZBH) Overvalued in 2026?
Based on GuruFocus' analysis, Zimmer Biomet Holdings stock appears to be undervalued.
The current stock price of CHF70.00 is trading 28.2% below its estimated GF Value™ of CHF97.46.
GuruFocus considers Zimmer Biomet Holdings to be Modestly Undervalued.
Key valuation signals for XSWX:ZBH:
ROA %: 4.13% (70% above median its 10-year median of 2.43)
GF Value™: CHF97.46 vs. price of CHF70.00 (28.2% below fair value)
Industry Position: 600% above the Medical Devices & Instruments median (#315 of 857)
No single metric tells the full story. See the XSWX:ZBH stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.
65GF Score
Get the complete analysis for XSWX:ZBH
ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:ZBH has been successfully added to your 
